LPOXY Therapeutics, Inc. Acquires Key Assets from Xeno Biosciences Inc. to Advance C. difficile Prevention Therapy
LPOXY Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on innovative therapies for infectious disease prevention, announced today that it has signed a term sheet to acquire selected assets from Xeno Biosciences Inc. The assets include regulatory filings, correspondence, and documentation from FDA and global regulatory interactions, as well as comprehensive CMC data. LPOXY will benefit from ownership of data generated in Xeno’s Phase I and Ib clinical trials, which validates the safety of the Active Pharmaceutical Ingredient shared by Xeno’s and LPOXY’s drug products. In exchange, Xeno will become a shareholder in LPOXY Therapeutics and may receive milestone payments totaling up to $7.5 million. Dennis Kim, MD, CEO of Xeno Biosciences, will join LPOXY’s Board of Directors. Read more >>